流感多发，孩子这类易感人群，该如何更好地防护和治疗？ 上午8点，北京儿童医院三层的内科、呼吸科诊室门口已经有患儿和家长在等候就诊了。记者看到，一些患儿家长拿着挂号单直接来到分诊台 进行检查开单。 除了可以现场提前开检查单以外，患儿家长还可以在手机上自行操作。 北京儿童医院的诊前开单机制，大幅缩短了患儿在医院的等待时间，患儿就诊时可直接将诊前检查的结果交给医生进行精准判断，及时制定治 疗方案。除此之外儿童医院还采取了多种措施保障患儿应看尽看。 北京儿童医院门诊部主任 李豫川：我们24小时接诊，不限号，设置了白班、小夜班和大夜班，这样患儿在任何时间段来到医院都可以得到接 诊。此外，我们还有互联网夜班门诊，也是专门针对内科发热咳嗽的孩子，在18:30以后开诊。 治疗儿童流感 护士详细询问患儿的基本情况后，分诊台就可以直接为发热、咳嗽、呕吐及腹泻的患儿提前开具退烧药，以及血常规，甲、乙流核酸，支原体 核酸等检测的检查单。这样的诊疗流程受到了很多患儿家长的点赞。 专家介绍，识别和判断流感的早期症状非常关键，不同年龄段的症状表现有所不同。 专家提醒：流感防治重在早识别、早治疗，感染后的24—48小时内，病毒的复制活动达到 ...

来源：郑州日报 专家详解防治热点问题 本报讯(记者 邢进 通讯员 任鹏飞)近日，随着流感病毒进入高发期，各医院儿科门诊量显著上升，不少 儿童出现高烧、咳嗽、肌肉酸痛等流感症状。许多家长在孩子生病时容易"病急乱投医"，河南省妇幼保 健院(郑州大学第三附属医院)药学专家提醒，盲目用药存在风险，正确使用抗流感药物至关重要。 普通感冒≠流感 据了解，目前国内适用于儿童的主流抗流感药物主要为奥司他韦(颗粒/胶囊)和玛巴洛沙韦，但并非所有 感冒情况都适用。医生指出，使用抗流感药物需满足以下条件：一是经医生确诊为流感，通常伴有高 烧、肌肉酸痛、咳嗽、乏力等症状；二是应在发病48小时内开始服药，越早效果越好，超过48小时后疗 效可能打折扣。 专家特别提醒，流感与普通感冒不同，抗菌药物对流感无效。此外，奥司他韦既可用于治疗，也可在密 切接触流感患者后作为预防用药，但需严格遵医嘱；而玛巴洛沙韦目前仅适用于5岁以上儿童的治疗， 不能用于预防。 奥司他韦： 用药需精准，疗程要完整 在儿童用药方面，奥司他韦的剂量需根据体重精确计算，一般为每日约3.0mg/kg，分两次服用。不同品 牌药物浓度可能存在差异，家长应仔细核对说明书。 为减轻 ...

Core Viewpoint - The article emphasizes the importance of understanding and preventing influenza, particularly the H3N2 strain, which is currently the dominant virus affecting children, especially those under two years old [1] Group 1: Influenza Overview - Influenza viruses are categorized into four types: A, B, C, and D, with type A being the most likely to cause seasonal outbreaks and pandemics [1] - The H3N2 subtype has replaced H1N1 as the primary circulating strain since July of this year, leading to an increased risk of transmission due to a lack of targeted immune memory in susceptible populations [1] Group 2: Symptoms and Identification - Influenza typically presents with sudden onset, high fever (39-40°C), headaches, muscle aches, and significant fatigue, while upper respiratory symptoms may be mild [3] - In contrast, common colds primarily exhibit upper respiratory symptoms with milder overall effects [3] Group 3: Special Populations and Symptoms - Special attention is needed for children, who may exhibit gastrointestinal symptoms like nausea, vomiting, and diarrhea more frequently than adults [4] - Infants may show subtle symptoms, such as low-grade fever, lethargy, refusal to feed, and respiratory pauses [4] Group 4: Warning Signs for Severe Cases - Immediate medical attention is required for children showing signs of severe influenza, including extremely high fever (≥41°C), abnormal breathing rates, neurological symptoms, feeding difficulties, and exacerbation of underlying conditions [5] Group 5: Preventive Measures - Recommendations for preventing influenza in children include maintaining a healthy lifestyle, minimizing exposure to sick individuals, practicing respiratory etiquette, ensuring environmental cleanliness, and seeking timely medical care if symptoms arise [6] - Antiviral medication is advised for high-risk children who cannot receive vaccines or have not developed sufficient immunity [6] - Vaccination is highlighted as the most effective and economical method for preventing influenza [7] Group 6: Treatment Protocols - The first 48 hours after symptom onset is considered the "golden window" for antiviral treatment, with recommendations for high-risk groups to receive treatment even after this period [9] - Treatment should be guided by a physician, avoiding self-medication or dosage adjustments [9] - Supportive care is crucial for mild cases, while severe cases may require immediate medical intervention [9]

Core Viewpoint - Jiangsu Kangyuan Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for clinical trials of Jinzhen Oral Liquid for the treatment of children's influenza, indicating a significant step in expanding its market potential [1][2]. Group 1: Drug Development and Market Situation - Jinzhen Oral Liquid is a proprietary traditional Chinese medicine for children, composed of eight herbal ingredients, and has been included in the National Essential Medicines List and the National Medical Insurance Directory [2]. - The new indication for Jinzhen Oral Liquid targets children's influenza, a respiratory infectious disease caused by the influenza virus, with studies showing its efficacy in reducing viral load and improving lung health [2][3]. - The annual infection rate of influenza among children under five in China is reported to be as high as 20%-30%, with certain peak seasons reaching around 50%, highlighting the significant market opportunity for Jinzhen Oral Liquid [3]. Group 2: Financial Performance and Future Steps - The projected revenue for Jinzhen Oral Liquid in 2024 is approximately 81.52 million yuan [4]. - Following the receipt of the clinical trial approval, the company must complete Phase II and III clinical trials and submit the registration application for the drug [4].